T. Rowe Price Investment Management, Inc. Iovance Biotherapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,050,500 shares of IOVA stock, worth $20 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,050,500
Previous 1,313,339
56.13%
Holding current value
$20 Million
Previous $19.5 Million
15.51%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding IOVA
# of Institutions
320Shares Held
238MCall Options Held
1.27MPut Options Held
1.68M-
Vanguard Group Inc Valley Forge, PA26MShares$253 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY25.9MShares$253 Million6.02% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$234 Million28.39% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$207 Million0.0% of portfolio
-
State Street Corp Boston, MA12.6MShares$123 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.54B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...